Government-Owned Inventions; Availability for Licensing
Health and Human Services Department; National Institutes of Health · 2011
Read Government-Owned Inventions; Availability for Licensing by Health and Human Services Department; National Institutes of Health (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-19817.txt.
Description
Notice published in the Federal Register on 2011-08-04 by Health and Human Services Department; National Institutes of Health. Text from federalregister.gov (official edition: govinfo). [Pages 47217-47218] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-19817] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, Public Health Service, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The inventions.
Catalog record
| CREATOR | Health and Human Services Department; National Institutes of Health |
|---|---|
| YEAR | 2011 |
| COLLECTION | LAW |
| FORMAT | TXT |
| FILE SIZE | 9 KB |
| VERSION | 1.0 |
| LICENSE | Public Domain |
| RIGHTS | PUBLIC DOMAIN |
| SOURCE | Federal Register |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Government-Owned Inventions; Availability for Licensing
Citation: us:fr:2011-19817
Creator: Health and Human Services Department; National Institutes of Health
Year: 2011
Source-URL: https://www.federalregister.gov/documents/2011/08/04/2011-19817/government-owned-inventions-availability-for-licensing
Context: Notice published in the Federal Register on 2011-08-04 by Health and Human Services Department; National Institutes of Health. Text from federalregister.gov (official edition: govinfo).
[Pages 47217-47218]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-19817]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
CDK4-Transformed Mouse Podocytes Useful for Studying Glomerular
Diseases
Description of Technology: Podocytes, cells of the visceral
epithelium in the kidneys, are a key component of the glomerular
filtration barrier. Podocyte damage and loss contribute to the
initiation of glomerular diseases. Cyclin-dependent kinase 4 (CDK4), a
catalytic subunit of the cyclin D-CDK4 serine/threonine kinase complex,
is a critical regulator of the cell cycle. Recent studies showed that
cells immortalized with CDK4 are useful to study pathophysiology. NIH
investigators have generated mouse podocytes transformed with CDK4 as a
nonviral immortalizing gene. These transformed podocytes show podocyte
characteristics and express podocyte markers. Furthermore, confluent
CDK4-podocyte cultures show higher levels of gene expression for
multiple podocyte differentiation genes compared with subconfluent or
lower density culture.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
Potential Commercial Applications:
Model system for study of glomerular disorders.
Useful tools to study podocyte biology.
Competitive Advantage: Better model system to study podocyte
structure and function.
Inventors: Drs. Toru Sakairi and Jeffrey B. Kopp (NIDDK).
Publication: Sakairi T, et al. Cell-cell contact regulates gene
expression in CDK4-transformed mouse podocytes. Am J Physiol Renal
Physiol. 2010 Oct;299(4):F802-809. [PMID: 20668098].
Intellectual Property: HHS Reference No. E-287-2010/0--Research
Tool (Materials available for licensing: CDK4 podocytes). Patent
protection is not being pursued for this technology.
Related Technology: HHS Reference No. E-049-2007/0--Model for Study
of Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell
Line with Tet-on-Regulated Gene Expression (Dr. Jefferey B. Kopp,
NIDDK).
Licensing Contact: Suryanarayana (Sury) Vepa, PhD; 301-435-5020;
[email protected].
Conditionally Immortalized Human Podocyte Cell Lines
Description of Technology: Podocytes, cells of the visceral
epithelium in the kidneys, are a key component of the glomerular
filtration barrier. Podocyte damage and loss contribute to the
initiation of glomerular diseases. NIH investigators recently
established long-term urinary cell cultures from two patients with
focal segmental glomerulosclerosis and two healthy volunteers, via
transformation with the thermosensitive SV40 large T antigen (U19tsA58)
together with human telomerase (hTERT). Characterization of randomly
selected clonal cell lines from each human subject showed mRNA
expression for the podocyte markers synaptopodin, nestin, and CD2AP in
all clones. Podocin mRNA was absent from all clones. The expression of
nephrin, Wilms tumor 1 (WT1), and podocalyxin mRNA varied among the
clones, which may be due to transformation and/or cloning. These novel
human urine-derived podocyte-like epithelial cell lines (HUPECs)
generated from urine of patients and healthy volunteers will be useful
to study podocyte cell biology.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
Potential Commercial Applications:
Model system for study of glomerular disorders.
Useful tools to study podocyte biology.
Competitive Advantage: These podocyte-like cells are unique and
novel compared to the currently available podocyte cells because these
are obtained from individuals with glomerular disease.
Inventors: Drs. Toru Sakairi and Jeffrey B. Kopp (NIDDK).
Publication: Sakairi T, et al. Conditionally immortalized human
podocyte cell lines established from urine. Am J Physiol Renal Physiol.
2010 Mar;298(3):F557-67. [PMID: 19955187]
Intellectual Property: HHS Reference No. E-252-2010/0--Research
Tool. Patent protection is not being pursued for this technology.
Related Technologies:
HHS Reference No. E-049-2007/0--Model for Study of
Glomerular Disorders: Conditionally-Immortalized Mouse Podocyte Cell
Line with Tet-on-Regulated Gene Expression (Dr. Jefferey B. Kopp,
NIDDK).
HHS Reference No. E-287-2010/0--CDK4-Transformed Mouse
Podocytes Useful for Studying Glomerular Diseases (Drs. Toru Sakairi
and Jeffrey B. Kopp, NIDDK)
Licensing Contact: Suryanarayana (Sury) Vepa, PhD; 301-435-5020;
[email protected].
An In-Vitro Cell System Useful For Identification of ROR[gamma]
Antagonists
Description of Technology: The retinoid-related orphan receptors
alpha, beta and gamma (ROR[alpha], [beta] and [gamma], also referred to
as NR1F1, 2 and 3, respectively) comprise a distinct subfamily of
nuclear receptors. Study of ROR-deficient mice has implicated RORs in
the regulation of a number of biological processes and revealed
potential roles for these proteins in several pathologies. NIH
investigators have developed an in-vitro system using CHO cells stably
expressing a TET-On expression vector regulating ROR[gamma] and a RORE-
Luciferase reporter. This system
[[Page 47218]]
allows inducible expression of ROR[gamma] upon addition of doxycycline.
Upon its induction ROR[gamma] binds to the RORE in the luciferase
reporter plasmid and induces luciferase. This system can be used to
identify ROR[gamma] antagonists. This system has been tested
successfully in 1536-well plate high throughput analysis.
Potential Commercial Applications: Identification of therapeutic
compounds to treat asthma, inflammation, and various autoimmune
diseases such as osteoarthritis, multiple sclerosis.
Competitive Advantages: Novel and unique system to screen and
identify chemical and drugs for their ROR[gamma] antagonistic activity.
Development Stage:
Early-stage.
Pre-clinical.
In vitro data available.
Inventors: Drs. Yukimasa Takeda and Anton M. Jetten (NIEHS).
Publications:
1. Jetten AM. Retinoid-related receptors (RORs): Critical roles in
development, immunity, circadian rhythm, and cellular metabolism. Nucl
Recept Signal. 2009;7:1-32. [PMID: 19381306].
2. Yang XO, et al. T helper 17 lineage differentiation is
programmed by orphan receptors ROR alpha and ROR gamma. Immunity 2008
Jan;28(1):29-39. [PMID: 18164222].
3. Kurebayashi S, et al. Retinoid-related orphan receptor gamma
(RORgamma) is essential for lymphoid organogenesis and controls
apoptosis during thymopoiesis. Proc Natl Acad Sci USA. 2000 Aug
29;97(18):10132-10137. [PMID:10963675].
Intellectual Property: HHS Reference No. 253-2010/0--Research Tool.
Patent protection is not being pursued for this technology.
Related Technology: HHS Reference No. E-222-2009/0--RORgamma (RORC)
Deficient Mice Which Are Useful for the Study of Lymph Node
Organogenesis and Immune Responses (Dr. Anton M. Jetten, NIEHS).
Licensing Contact: Suryanarayana (Sury) Vepa, PhD; 301-435-5020;
[email protected].
Collaborative Research Opportunity: The NIEHS, Laboratory of
Respiratory Biology, Cell Biology Group, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize retinoid-
related orphan receptors (RORs) function in chronic diseases. For
collaboration opportunities, please contact Elizabeth M. Denholm, PhD
at [email protected].
Dated: July 27, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-19817 Filed 8-3-11; 8:45 am]